ThursdayOct 06, 2022 2:31 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Elevating Performance with Expanded Team

Flora Growth Corp. (NASDAQ: FLGC), throughout 2022, has been implementing its hiring strategy that has seen the appointment of several key individuals whose proven talents and productivity are critical to the company’s goal of delivering the most compelling customer experiences. “Flora Growth ushered in the new year with the appointment of Tim Leslie as chairman of its newly formed advisory board. It would later bring Derek Pedro, an industry-leading cannabis genetics and cultivation expert, on board as an advisor and named Vessel founder James Choe as chief strategy officer. In February 2022, Flora Growth announced the appointment of Jessie Casner…

Continue Reading

ThursdayOct 06, 2022 2:15 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Redefining Drug Delivery Platforms

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes, and dementia, among others. These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology…

Continue Reading

WednesdayOct 05, 2022 11:41 am

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Ideally Poised as Growing Consensus Points to Lidar as Essential Solution

Cepton (NASDAQ: CPTN), a developer of lidar-based solutions that help enable Advanced Driver Assistance Systems (“ADAS”), autonomous vehicles (“AVs”), smart cities, connected spaces, and smart industrial applications, is ideally poised as expert opinions concerning AV safety lean in favor of using lidar technologies in addition to HD cameras. “The safety of AVs and ADAS hinges on the ability of vehicle’s systems to sense surrounding objects. Both HD cameras and lidar have their benefits and drawbacks; however, lidar is coming out ahead as the technology advances and costs come down. Industry experts like Volkswagen CEO Herbert Diess confirm the growing consensus…

Continue Reading

TuesdayOct 04, 2022 12:00 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Positioned for Continued Growth Amid Prevailing Market Trends

Freight Technologies (NASDAQ: FRGT), a company that simplifies cross-border shipping and daily carrier operations through its B2B marketplace Fr8App, recently filed a Form F-1 with the Securities and Exchange Commission (“SEC”). “In the recently filed Form F-1, Fr8Tech, a British Virgin Islands-incorporated technology company developing supply chain optimization and automation solutions and providing its Fr8App platform for B2B cross-border shipping, registered more than 19 million ordinary shares for resale by selling shareholders identified in the form… Fr8Tech CEO Javier Selgas commented, ‘We are incredibly proud of our team, and thank them for their work and dedication to deliver our F-1…

Continue Reading

MondayOct 03, 2022 12:55 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company specializing in developing novel treatments for brain tumors, has focused on its lead drug candidate, Berubicin, to potentially treat glioblastoma (“GBM”). “CNS has since made significant headway, even receiving FDA Fast Track Designation, which now offers it an accelerated path to approval for Berubicin. ‘With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ noted CNS CEO John Climaco. GBM’s median survival from initial diagnosis is less than 15…

Continue Reading

FridaySep 30, 2022 3:18 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Working to Make a Difference in Underserved Patient Populations

QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of childhood cancer on the rise, the work of QSAM is becoming increasingly important… According to Children’s Cancer Cause, in 2022, an estimated 10,470 children (from birth to 14 years) and 5,480 adolescents (aged 15 to 19 years) will be diagnosed with cancer. ‘It is estimated that there will be 13.7 million cases of childhood cancer between 2020-2050. Unless there are major improvements in diagnosis and…

Continue Reading

FridaySep 30, 2022 1:31 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Expand Indications, Efficacy of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently received its 27th worldwide patent, granted in Mexico under registration #390001. “The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products. The latest patent provides value to the company through its continued pursuit of gaining regulatory approval for its patented DehydraTECH(TM)-enabled cannabidiol (‘CBD’) for the treatment of hypertension in regulated pharmaceutical applications. This has produced the claims necessary for the Mexico patent to use DehydraTECH-processed non-psychoactive cannabinoids to treat…

Continue Reading

MondaySep 26, 2022 3:39 pm

TinyGemsBreaks – Cepton Inc.’s (NASDAQ: CPTN) Short-Range Lidar Solution Aims to Bring Safety Benefits to Everyone on the Road

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of lidar-based solutions for autonomous vehicles (“AV”), advanced driver assistance systems (“ADAS”) and smart technology spaces, is leading the way with Nova, an award-winning short-range lidar solution that’s lightweight, flexible, energy-efficient, and easy to integrate into passenger and commercial vehicles. “CPTN recently announced the company’s collaboration with ZKW Group GmbH to demonstrate Nova at the IAA Transportation Conference… Cepton’s exhibit demonstrated how Nova helps eliminate blind spots and create a ‘safety cocoon’ around the vehicle by combining high-resolution, superior field of view coverage in all directions. Nova’s super-compact form additionally features flexible options…

Continue Reading

WednesdaySep 21, 2022 12:10 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24,…

Continue Reading

FridaySep 16, 2022 1:45 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of…

Continue Reading

Contact us: (310) 299-1717